Compare DexCom, Inc. (DXCM) vs Fabrinet (FN) Price & Performance

DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.

DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.

Fabrinet (FN) trades at $487.33, down 2.14% on the day, amid a mixed technical backdrop with a bullish moving average signal but overbought RSI readings. Fundamentally, the company demonstrates strong profitability with a 10.19% net income margin and 21.33% ROE, supported by consecutive quarterly EPS beats. Recent news highlights surging AI data center demand driving revenue growth, though the stock faces pressure from high capital expenditures and customer concentration concerns.

The outlook remains positive given robust analyst sentiment (75% buy ratings) and a consensus price target of $769.50, implying significant upside. Key opportunities include capacity expansion to capture AI infrastructure growth, while risks involve margin compression from spending and reliance on a few hyperscaler customers. Earnings acceleration and market positioning support a constructive view, but volatility may persist near-term.